Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 편욱범 | * |
dc.date.accessioned | 2022-02-14T16:30:07Z | - |
dc.date.available | 2022-02-14T16:30:07Z | - |
dc.date.issued | 2022 | * |
dc.identifier.issn | 2297-055X | * |
dc.identifier.other | OAK-31038 | * |
dc.identifier.uri | https://dspace.ewha.ac.kr/handle/2015.oak/260416 | - |
dc.description.abstract | Background: Clinical trials of non-vitamin K antagonist oral anticoagulants (NOACs) in patients with chronic heart failure and atrial fibrillation (AF) have demonstrated reduced risks of stroke and bleeding compared with vitamin K antagonists (VKAs). Here, we aim to assess the clinical efficacy and safety of rivaroxaban, a NOAC, compared with warfarin, a VKA, and the effects of rivaroxaban on cardiovascular biomarkers in patients with acute decompensated heart failure (ADHF) with reduced ejection fraction (& LE;40%) and AF.Methods: Rivaroxaban Once-daily vs. dose-adjusted vitamin K antagonist on biomarkers in Acute Decompensated Heart Failure and Atrial Fibrillation (ROAD HF-AF) is a randomized, open-labeled, controlled, prospective, multicenter pilot study designed to assess cardiovascular biomarkers and the safety of rivaroxaban (20 or 15 mg in patients with creatinine clearance 30-49 mL/min per day) compared with VKA (target international normalized range: 2-3) in 150 patients hospitalized with ADHF and AF. The primary endpoint is the change in circulating high-sensitivity cardiac troponin (hsTn) during hospitalization. The secondary endpoints are bleeding, hospital stay duration, in-hospital mortality, and changes in cardiovascular, renal, and thrombosis biomarkers. Patients will be followed for 180 days.Conclusion: We hypothesize that rivaroxaban will reduce myocardial injury and hemodynamic stress, as reflected by the biomarker status, within 72 h in patients with ADHF and AF, compared with VKA. We hope to facilitate future biomarker-based, large-scale outcome trials using NOACs in patients with ADHF and AF, based on the results of this multicenter, randomized, controlled study. | * |
dc.language | English | * |
dc.publisher | FRONTIERS MEDIA SA | * |
dc.subject | rivaroxaban | * |
dc.subject | acute decompensated heart failure | * |
dc.subject | atrial fibrillation | * |
dc.subject | vitamin K antagonist (VKA) | * |
dc.subject | biomarker | * |
dc.title | Rivaroxaban Once-Daily vs. Dose-Adjusted Vitamin K Antagonist on Biomarkers in Acute Decompensated Heart Failure and Atrial Fibrillation (ROAD HF-AF): Rationale and Design of an Investigator-Initiated Multicenter Randomized Prospective Open-Labeled Pilot Clinical Study | * |
dc.type | Article | * |
dc.relation.volume | 8 | * |
dc.relation.index | SCIE | * |
dc.relation.index | SCOPUS | * |
dc.relation.journaltitle | FRONTIERS IN CARDIOVASCULAR MEDICINE | * |
dc.identifier.doi | 10.3389/fcvm.2021.765081 | * |
dc.identifier.wosid | WOS:000748027600001 | * |
dc.author.google | Cho, Iksung | * |
dc.author.google | Oh, Jaewon | * |
dc.author.google | Kim, In-Cheol | * |
dc.author.google | Chung, Hyemoon | * |
dc.author.google | Lee, Jung-Hee | * |
dc.author.google | Kim, Hyue Mee | * |
dc.author.google | Byun, Young Sup | * |
dc.author.google | Yoo, Byung-Su | * |
dc.author.google | Choi, Eui-Young | * |
dc.author.google | Chung, Wook-Jin | * |
dc.author.google | Pyun, Wook Bum | * |
dc.author.google | Kang, Seok-Min | * |
dc.contributor.scopusid | 편욱범(6508352922) | * |
dc.date.modifydate | 20240123092816 | * |